Torrent Pharmaceuticals has announced that the U.S. FDA has issued an Establishment Inspection Report (EIR) for its manufacturing facility at Indrad, Gujarat. The inspection, conducted from June 3 to June 12, 2024, has been classified as Voluntary Action Indicated (VAI). The inspection process is now officially closed.